PSNL

Personalis Inc

May 19 • 04:00PM ET

7.04

+0.32 4.76 %

Healthcare • Diagnostics & Research • USA • Small • NASD

| Held by: ARKG VTI IWM VXF IBB IWN DFAS VTWO DFMC DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.02	Insider Own	40.83%	Shs Outstand	104.69M	Perf Week	16.56%
Market Cap	737.24M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.51%	Shs Float	61.97M	Perf Month	11.04%
Enterprise Value	542.80M	PEG	-	EPS next Q	-0.26	Inst Own	62.35%	Short Float	21.15%	Perf Quarter	-21.78%
Income	-95.55M	P/S	11.43	EPS this Y	-12.40%	Inst Trans	19.06%	Short Ratio	7.06	Perf Half Y	-6.26%
Sales	64.52M	P/B	2.89	EPS next Y	12.43%	ROA	-31.92%	Short Interest	13.10M	Perf YTD	-11.56%
Book/sh	2.43	P/C	3.16	EPS next 5Y	6.66%	ROE	-41.35%	52W High	11.50 -38.78%	Perf Year	40.24%
Cash/sh	2.23	P/FCF	-	EPS past 3/5Y	28.38% 2.91%	ROIC	-33.43%	52W Low	3.84 83.33%	Perf 3Y	224.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	2.30% -2.40%	Gross Margin	13.72%	Volatility	11.16% 9.17%	Perf 5Y	-67.53%
Dividend TTM	-	EV/Sales	8.41	EPS Y/Y TTM	21.16%	Oper. Margin	-158.91%	ATR (14)	0.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.44	Sales Y/Y TTM	-24.71%	Profit Margin	-148.11%	RSI (14)	60.12	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	6.57	EPS Q/Q	-60.02%	SMA20	16.70%	Beta	1.99	Target Price	10.86
Payout	-	Debt/Eq	0.15	Sales Q/Q	-24.91%	SMA50	8.37%	Rel Volume	1.01	Prev Close	6.72
Employees	260	LT Debt/Eq	0.12	Earnings	May 07 AMC	SMA200	-6.22%	Avg Volume	1.86M	Price	7.04
IPO	Jun 20, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.85% 6.81%	Trades		Volume	1,868,029	Change	4.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$11
May-15-25	Initiated	Guggenheim	Buy	$6
Mar-17-25	Initiated	Craig Hallum	Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy	$27 → $23
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy	$33 → $28
May-06-21	Upgrade	Oppenheimer	Perform → Outperform	$28
Jan-28-21	Initiated	Truist	Buy	$50
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral	$40
Nov-12-20	Reiterated	Needham	Buy	$25 → $32
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy	$35
Oct-08-20	Initiated	BTIG Research	Buy	$35
Aug-27-20	Initiated	H.C. Wainwright	Buy	$30
Aug-18-20	Initiated	Needham	Buy	$25
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy	$22

Show Previous Ratings

May-14-26 04:01PM	Personalis to Participate in Upcoming Investor Events (Business Wire) +5.01% -5.22%
May-13-26 06:00AM	Personalis Receives Medicare Coverage for NeXT Personal for Immunotherapy Monitoring Across Late-stage Solid Tumors (Business Wire) +5.79%
May-08-26 08:30AM	Personalis, Inc. Q1 2026 Earnings Call Summary (Moby)
May-07-26 04:53PM	Personalis: Q1 Earnings Snapshot (Associated Press)
04:01PM	Personalis Reports First Quarter Results and Recent Highlights (Business Wire)
04:01PM	Loading…
Apr-23-26 04:01PM	Personalis to Announce First Quarter 2026 Financial Results (Business Wire) -6.50%
Apr-21-26 06:00AM	Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 (Business Wire)
Apr-13-26 06:00AM	Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026 (Business Wire)
Apr-01-26 04:01PM	Personalis to Participate in the 25th Annual Needham Virtual Conference (Business Wire)
Mar-17-26 04:00PM	Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption (Business Wire)
Mar-12-26 06:00AM	Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal (Business Wire) -17.11%
Feb-27-26 08:30AM	Personalis, Inc. Q4 2025 Earnings Call Summary (Moby)
04:30AM	Personalis Q4 Earnings Call Highlights (MarketBeat)
12:02AM	Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... (GuruFocus.com)
Feb-26-26 05:30PM	Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +8.66%
04:26PM	Loading…
04:26PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire)
Feb-24-26 07:30PM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-17-26 04:01PM	Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference (Business Wire) +5.02%
Feb-12-26 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -5.73%
Feb-10-26 09:18AM	Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test (Benzinga) +10.09%
06:00AM	Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance (Business Wire)
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool) -9.67%
Feb-02-26 08:18PM	Personalis, Inc. (PSNL): A Bull Case Theory (Insider Monkey)
06:00AM	Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Jan-28-26 04:01PM	Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-12-26 04:00PM	Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker (Business Wire) +5.80%
Jan-08-26 08:00AM	Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire) -10.43%
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
12:19PM	Loading…
Dec-30-25 12:19PM	Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) (Insider Monkey)
Dec-17-25 06:00AM	Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors (Business Wire)
Dec-11-25 09:00AM	New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer (Business Wire)
Nov-18-25 04:01PM	Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire) +8.14%
Nov-05-25 12:11AM	Personalis Inc (PSNL) Q3 2025 Earnings Call Highlights: Strong Clinical Adoption Amid Revenue ... (GuruFocus.com) -12.26%
Nov-04-25 05:30PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 07:51AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q3 2025 Result (GuruFocus.com) -6.64%
Oct-21-25 04:01PM	Personalis to Announce Third Quarter 2025 Financial Results (Business Wire) -5.43% -6.74%
Oct-17-25 03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks) -11.19%
Oct-16-25 09:00AM	Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing (Business Wire) +20.52%
Sep-15-25 05:35PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks) +13.17%
Sep-10-25 04:05PM	CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test (Business Wire)
Sep-03-25 04:05PM	Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing (Business Wire)
Aug-27-25 04:01PM	Personalis to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 09:35AM	Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL) (Zacks) +5.69%
Aug-12-25 09:35AM	After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL) (Zacks)
Aug-08-25 12:00PM	All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy (Zacks)
06:00AM	Tempus Reports Second Quarter 2025 Results (Business Wire)
Aug-05-25 04:10PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance) -21.90%
04:01PM	Personalis Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 09:58AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q2 2025 Result (GuruFocus.com)
Jul-22-25 04:01PM	Personalis to Announce Second Quarter 2025 Financial Results (Business Wire) +5.13%
Jul-18-25 04:00PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
Jul-09-25 04:00PM	Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (Business Wire)
Jul-03-25 07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-17-25 10:40AM	Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-13-25 12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
Jun-03-25 04:00PM	Personalis' NeXT Personal Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO (Business Wire) +5.53%
Jun-02-25 04:00PM	New Data Shows NeXT Personal Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse (Business Wire)
May-22-25 06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection (Business Wire)
May-14-25 04:01PM	Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference (Business Wire) -6.23%
May-07-25 03:23AM	Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +21.00%
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.10%
04:01PM	Personalis Reports First Quarter 2025 Financial Results (Business Wire)
May-05-25 10:12AM	Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 08:05PM	Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-28-25 05:00PM	Personalis' NeXT Personal Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study (Business Wire)
Apr-22-25 06:47PM	Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey) +7.91% +7.92%
04:01PM	Personalis to Announce First Quarter 2025 Financial Results (Business Wire)
06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection (Business Wire)
Apr-17-25 04:15PM	The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor's Business Daily)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 04:01PM	Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-03-25 06:00AM	New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection (Business Wire)
Feb-28-25 04:00AM	Personalis Inc (PSNL) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:20PM	Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.36%
04:21PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 08:09AM	Personalis Inc (PSNL) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +5.91%
Feb-20-25 10:00AM	Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -6.78%
Feb-18-25 04:01PM	Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference (Business Wire) +9.62%
Feb-13-25 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results (Business Wire) +7.08% +10.42%
Jan-28-25 04:01PM	Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire) -6.37% -7.90%
Jan-20-25 12:00PM	Personalis (PSNL) Upgraded to Buy: Here's Why (Zacks)
Jan-13-25 11:09AM	Researchers find ctDNA test predicts lung cancer outcomes in study (Medical Device Network)
05:00AM	New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer (Business Wire)
Jan-07-25 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue (Business Wire) -6.71% -6.35%
Dec-21-24 07:30AM	Personalis price target raised to $8 from $7 at BTIG (TipRanks)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) +9.32%
Dec-19-24 09:00AM	Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna (Business Wire) +47.75%
Dec-18-24 03:00AM	Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma (Insider Monkey) -7.29%
Dec-16-24 08:00AM	Personalis and Tempus Expand Collaboration to Biopharma (Business Wire)
Nov-20-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -6.23%
Nov-07-24 10:01AM	Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ... (GuruFocus.com) -22.58%
Nov-06-24 05:25PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

CEO & DirectorMr. Christopher M. Hall

M.S.Dr. Richard Chen M.D.

CFO & COOMr. Aaron L. Tachibana

Ph.D.Dr. Russ B. Altman M.D.

FRCPDr. Euan Angus Ashley DPHIL

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tempus AI, Inc.	10% Owner	Nov 18 '25	Buy	7.67	64,750	496,632	12,783,550	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 25 '25	Buy	10.62	23,600	250,665	12,918,346	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 22 '25	Buy	8.93	28,000	250,040	13,039,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 21 '25	Buy	9.40	26,499	249,190	12,869,521	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 24 '25	Buy	9.87	25,225	248,971	12,894,746	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 19 '25	Buy	8.12	30,645	248,837	12,814,195	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 20 '25	Buy	8.63	28,827	248,777	12,843,022	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 17 '25	Buy	7.86	31,650	248,769	12,949,996	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 19 '25	Buy	8.39	29,641	248,688	13,011,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 18 '25	Buy	7.91	31,430	248,611	12,981,426	Feb 13 05:24 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Option Exercise	9.16	1,201	11,001	165,659	Jan 23 06:03 PM
Tachibana Aaron	CFO AND COO	Jan 22 '26	Sale	11.50	1,201	13,812	164,458	Jan 23 06:03 PM
AARON L TACHIBANA	Officer	Jan 22 '26	Proposed Sale	9.65	40,000	386,000		Jan 22 04:34 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Option Exercise	9.16	103,668	949,599	268,126	Nov 28 05:09 PM
Tachibana Aaron	CFO AND COO	Nov 25 '25	Sale	10.78	103,668	1,117,541	164,458	Nov 28 05:09 PM
AARON L TACHIBANA	Officer	Nov 25 '25	Proposed Sale	9.99	103,668	1,035,643		Nov 25 04:51 PM
Hall Christopher M	PRESIDENT AND CEO	Nov 03 '25	Sale	8.99	29,612	266,212	148,486	Nov 05 04:05 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jul 28 '25	Sale	6.57	452	2,970	124,505	Jul 30 04:20 PM
Tachibana Aaron	CFO AND COO	Jul 28 '25	Sale	6.57	641	4,211	164,458	Jul 30 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSNL

Personalis Inc

Upgrade your Finviz experience